090435:KRXAmorepacific Corporation Analysis
Data as of 2026-05-28 - not real-time
₩38,100.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Amorepacific’s stock is trading well below its 20‑day (44,038 KRW), 50‑day (45,902 KRW) and 200‑day (44,964 KRW) moving averages, indicating a pronounced short‑term weakness. The RSI of 27 signals that the shares are technically oversold, while a bearish MACD histogram reinforces downside momentum. Despite this, the company boasts a solid 3.2% dividend yield with a comfortable payout ratio (~37%) and a strong cash position that far exceeds its debt load.
Fundamentally, the DCF‑derived fair value of roughly 122,000 KRW is more than three times the current price, suggesting deep undervaluation. Revenue is growing at a healthy 6.4% YoY, supported by robust gross margins (~73%) and a diversified beauty portfolio. However, a high debt‑to‑equity ratio (~6.4) and modest ROE (~4.4%) temper optimism. The blend of defensive consumer exposure, attractive yield, and valuation gap points to upside potential, especially if the price can recover from its current support level.
Fundamentally, the DCF‑derived fair value of roughly 122,000 KRW is more than three times the current price, suggesting deep undervaluation. Revenue is growing at a healthy 6.4% YoY, supported by robust gross margins (~73%) and a diversified beauty portfolio. However, a high debt‑to‑equity ratio (~6.4) and modest ROE (~4.4%) temper optimism. The blend of defensive consumer exposure, attractive yield, and valuation gap points to upside potential, especially if the price can recover from its current support level.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- RSI indicates oversold conditions
- Price below all major SMAs
- Bearish MACD momentum
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF valuation gap suggests upside
- Strong cash generation and dividend yield
- Moderate revenue growth with high margins
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Established global brand portfolio
- Sustainable dividend and cash surplus
- Long‑term undervaluation despite leverage
Key Metrics & Analysis
Financial Health
Revenue Growth6.40%
Profit Margin5.40%
ROE4.43%
ROA3.10%
Debt/Equity6.44
Op. Cash Flow₩526.3B
Free Cash Flow₩442.7B
Technical Analysis
TrendNeutral
RSI27.2
Support₩37,700.00
Resistance₩53,200.00
MA 20₩44,037.50
MA 50₩45,902.00
MA 200₩44,963.75
MACDBearish
VolumeDecreasing
Fear & Greed Index91.63
Valuation
Fair Value₩122,087.97
GradeUndervalued
TypeBlend
Dividend Yield3.20%
Risk Assessment
Beta0.17
Volatility41.79%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.